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Pemphigus foliaceus is associated with an autoim-
mune response against desmoglein-1; however, the 
fine specificity of these autoantibodies and the role 
that they play in pathogenesis have not yet been 
elucidated. In an attempt to develop a system to 
facilitate the detection and characterization of this 
antigen/antibody system, recombinant human des-
moglein-1 was expressed in COS-1 cells, a mamma-
lian epithelial cell line. The desmoglein-1 transgene 
product was shown to be expressed on the surface of 
the COS-1 cells in the appropriate transmembrane 
orientation. All pemphigus foliaceus sera (endemic 
form, n = 24; nonendemic form , n = 7) reacted 
strongly with nonpermeabilized desmoglein-1-trans-
he clinical, histologic, and immunologic features 
characteristic of idiopathic pemphigus foliaceus (PF) 
[1,2] are also seen in fogo selvagem (FS), a form of 
PF that is endemic to certain rural regions of Brazil 
[3- 5]. Autoantibodies produced by PF patients are 
pathogenic, as shown by passive-transfer studies [6], and exhibit an 
IgG4 subclass restriction [7,8]. It is interesting that F(ab)2 and 
univalent Fab I fragments generated from PF IgG also were found to 
be highly active in inducing the subcorneal blistering disease in the 
skin of injected animals [9]. T h ese findings suggested that epider-
mal cell detachment m ay be initiated by simple binding of a 
population of autoan tibodies to a target antigen, possibly impairing 
the function of a keratin ocyte adhesion molecule. 
Several independent lines of study have identified desmoglein-l, 
a 160-kD transmembrane glycoprotein constituent of the desmo-
some, as a major target of PF autoantibodies. Desmoglein-l is 
recognized by about one third of PF sera by immunoblot analysis 
[10] and is immunoprecipitated by 100% ofPF sera [11]. PF and FS 
sera also have been shown to react specifically with an 80-kD 
antigen solubilized from human or bovine epidermal envelope 
preparations [12-14]. This 80-kD glycopeptide recently has been 
shown by amino acid sequence analysis to be an N-terminal 
fragment of desmoglein-l [15]. Cloning and sequence analysis have 
Manuscript received August 3, 1994; revised November 4, 1994; ac-
cepted for publication November 21, 1994. 
Reprint requests to: Dr. George J. Giudice, Department of Dermatology, 
Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, 
WI 53226. 
Abbreviations: BP, bullous pemphigoid; FS, fogo selvagem; PF, pemphi-
gus foliaceus; PV, pemphigus vulgaris; rDsg1, recombinant desmoglein-1. 
fected cells, exhibiting a punctate cell-surface stain-
ing pattern. This reactivity against the desmoglein-1 
ectodomain was predominantly an IgG4-restricted 
response and was calcium dependent. Ten of 18 
pemphigus vulgaris sera also reacted with the extra-
cellular domain of recombinant desmoglein-1. Use of 
this eukaryotic expression system should greatly fa-
cilitate further characterization of the anti-desmo-
glein-1 autoimmune response associated with pem-
phigus foliaceus and pemphigus vulgaris and may aid 
in determining its pathogenic relevance. K ey words: 
desmosome/autoimmunity/cadherin/skin. J Invest Dermatol 
104:323-328, 1995 
identified desmoglein- l as a member of the family of calcium-
dependent cell adhesion molecules known as the cadherins [1 6-
20]. Figure 1 shows a schematic diagram of the domain organiza-
tion of desmoglein- l. 
We have shown previously by immunoblot analysis that seg-
ments of the human desmoglein-l ectodomain, when expressed as 
fusion proteins in a bacterial system, are recognized by PF autoan-
tibodies [21]. Approximately half of the PF sera that were tested 
showed some reactivity in this system, even though all of them 
were known to react with desmoglein-l in an immunoprecipitation 
assay. Based on these and other data [13,14,22], it has been 
postulated that pathogenic autoantibodies in PF and FS may well 
recognize conformational, rather than linear, epitopes on desmo-
glein- l. 
In the present study, a recombinant form of desmoglein-l 
(rDsgl) was generated in a mammalian expression system and 
analyzed for reactivity with PF and FS autoantibodies. In contrast to 
the limited number of patient sera that reacted with rDsgl ex-
pressed in bacteria [21], all PF sera that were tested showed specific 
reactivity with the extracellular domain of rDsgl expressed by 
COS-l cells. This system may prove to be useful in defining the 
subclass restriction and fine specificity of pathogenic autoantibodies 
produced by PF and FS patients. 
MATERIALS AND METHODS 
Source o f H uman Ser a Sera were obtained from the following groups 
of individuals: FS patients living in endemic areas of Brazil (n = 24), 
unaffected blood relatives of FS patients living in the same endemic areas 
(n = 14). unaffected individuals living in the endemic areas of Brazil with no 
family history of FS (n = 12), PF patients from the United States (n = 7), 
pemphigus vulgaris (PV) patients (n = 18), bullous pemphigoid (BP) 
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Figure 1. Schematic diagram of the recombinant forms of desmo-
glein-l (Dsgl) used in this study. The figure at the top represents the 
unprocessed form of human desmoglein-1, showing the signal sequence (S), 
the propeptide (P), and the transmembrane domain (TM). The putative cell 
adhesion recognition sequence (RAL) and the putative calcium-binding 
domains (ovals) are shown. The bar labeled rDsg1A represents the polypep-
tide encoded by the pSVL-DG1A construct. The three smaller bars under-
neath indicate the relative sizes and positions of the desmoglein-1 segments 
contained in fusion proteins FP1, FP3 , and FP4. 
patients (n = 12), and normal volunteers (n = 12) . BP and all forms of 
pemphigus were diagnosed in all patients using clinical, histologic, and 
immunologic criteria as described previously [1-5,23]. 
Generation ofDesmoglein-l Expression Constructs Three overlap-
ping partial desmoglein-1 cDNA segments were cloned from human 
keratinocyte cDNA libraries using a polymerase chain reaction- based 
protocol and were subcloned into the pCR-II vector (Invitrogen, San 
Diego, CA). The human desmoglein-1 oligodeoxynucleotide primers were 
synthesized by Operon, Inc. (Alameda, CA) and were based on the 
published sequence [16-19]. The 5' portion of the desmoglein-1 transcript 
was amplified by polymerase chain reaction from a random-primed human 
keratinocyte cDNA library (Clontech Laboratories, Palo Alto, CA) using 
the positive strand primer 63-pos (5' -GAGAA TCCAGCAGAGATGG-3') 
and the negative strand primer 777-neg (5'-CATACTGGCCGTATT-
GCTCTCTGTCTAG-3 ') . The desmoglein-1 portion corresponding to 
nucleotides 750 to 1259 was amplified from an oligo-dT -primed library 
with primers 750-pos (5' -CT AGACAGAGAGCAA T ACGGCCAGTAT-
3') and 1259-neg (5'-TACAACATATGTCTTTGA-3'). The last set of 
primers, 1242-pos (5'-TCAAGACATATGTTGTA-3') and 2017-neg (5'-
CCTCCCAGATCTTGCATTT-3'), was used to amplify the human cDNA 
encoding the transmembrane domain and portions of the extracellular and 
cytoplasmic domains of desmoglein-l. These three desmoglein-1 cDNAs 
were joined at the unique internal EaeI and NdeI sites while still in the 
pCR-II vector. The 2-kb EcoRV IBamHI desmoglein-1 insert was sub-
cloned into the SmaIlBamHI site of the eukaryotic expression vector, pSVL 
(Pharmacia Biotech, Inc., Piscataway, N]), generating the construct pSVL-
DG1A. The desmoglein-1 insert was shown by sequence analysis to be 
identical to the human desmoglein-1 sequence reported by Goodwin et al 
[16] . The nucleotide and deduced amino acid sequence information was 
analyzed using the GCG software package [24] . A schematic diagram of the 
polypeptide expressed by pSVL-DG 1A is shown in Fig 1. 
Generation of Rabbit Anti-Desmoglein-l Antisera Three segments 
of the human desmoglein-1 protein were expressed in Escherichia coli as 
glutathione S-transferase fusion proteins using the pGEX system (Pharmacia 
Biotech, Inc.). The portions of desmoglein-1 contained in each fusion 
protein are as follows: FP1, amino acids 76-158; FP3, amino acids 424-510; 
FP4, amino acids 567-667 (amino acid 1 corresponds to the amino terminus 
of the mature form of desmoglein-1). The size and position of each of the 
desmoglein-1 fusion proteins are depicted in the schematic diagram shown 
in Fig 1. These three glutathione S-transferase-desmoglein-1 fusion pro-
teins were purified by glutathione affinity chromatography and were used to 
immunize New Zealand White rabbits, as described previously [25]. The 
specificities of these antisera (designated R-FP1, R-FP3, and R -FP4) were 
characterized by immunoblot and indirect immunofluorescence (IF) analy-
sis, as described below. 
Transfection ofCO S- l Cells COS-1 cells were plated at approximately 
50% confluence in eight-well Lab-Tek chamber slides (Nunc, Naperville, 
IL) 1 d before transfection. Transfection was carried out by the following 
method. The culture medium was removed and the cells were rinsed with 
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1 X phosphate-buffered saline . The transfection cocktail (1 X phosphate-
buffered saline, pH 7.4, 120 ng supercoiled plasmid DNA per chamber, 
1 J.LM diethylaminoethyl-dextran) was then added to the culture chamber 
(60 J.LI per chamber). After a 1-h incubation at 37°C, 200 J.LI of 9.2-mM 
chloroquine in Dulbecco's modified Eagle's medium (DME) was added to 
each chamber and incubated at 37°C for an additional 2.5 h. The transfec-
tion mixture was then removed from each chamber, and a solution of 10% 
dimethylsulfoxide/DME was added and incubated at room temperature for 
2.5 min. The cells were then incubated in fresh medium at 37°C. The 
medium was changed after 24 h, and the cells were analyzed 48 h after DNA 
addition. 
Immu n o lo gic Analysis of T ransfectants COS-1 transfectants were 
analyzed immunologically using previously described indirect IF and im-
munoblotting protocols [13,14,26-28], which were modified as described 
below. Unless otherwise stated, IF analyses were performed on nonperme-
abilized cells in TBS + Ca++ (10 mM Tris, pH 7.5,150 mM NaCI, 1 mM 
calcium, and 10% fetal bovine serum; Hyclone Laboratories, Logan, UT). 
To determine the transmembrane orientation of the desmoglein- 1 trans gene 
product, some COS cell preparations were antibody labeled after a 15-min 
fixation in 100% methanol at - 20°C. Human patient and control sera were 
diluted 1:100 in TBS + Ca++ , whereas rabbit antisera, R -FP1, R -FP3, 
R-FP4, and the corresponding preimmune sera were used at a 1 :200 
dilution. Mter incubation with the primary antibody, the cultured cells were 
treated for 30 min with a 1 :500 dilution of biotinylated mouse antibodies 
specific for human IgG1, IgG2, IgG3, or IgG4 (Zymed Laboratories, San 
Francisco, CA), and subsequendy labeled with a 1 :200 dilution of fluores-
cein isothiocyanate-streptavidin (Zymed Laboratories, San Francisco, CA) . 
Human epidermis was prepared and extracted as described previously [13]. 
To reduce background reactivity seen on immunoblots with certain anti-
sera, the diluted sera (10 ml vol) were pre adsorbed overnight at room 
temperature with a protein blot containing a total cell extract prepared from 
one T75 flask of untransfected COS-1 cells. 
RESULTS 
Recombinant Desmoglein-l is Expresse d o n t h e Su rfa ce o f 
Transfected COS- l Cells COS-l cells were transfected with 
the expression construct pSVL-DGIA using a standard diethylami-
no ethyl-dextran protocol. As determined by indirect IF analysis, 
the transfection efficiency was approximately 55%. The transfec-
tants were analyzed by irnmunoblot using the R -FP3 anti- desmo-
glein-l antiserum; the results are shown in Fig 2. This antiserum 
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Figu re 2. The d esmoglein-l (Dsg-l) transgene is expressed in 
COS-l c ells. Immunoblots contain the glutathione S- transferase-desmo-
glein-1 fusion protein, FP3 (lift), a human epidermal total protein extract 
(middle), and total protein extracts from COS- 1 cells transfected with either 
pSVL or the pSVL-DG 1A construct (Dsg-1; right). The blots were labeled 
with either the pre- or post-immune serum, R-FP3. Arrows on the lift, 
middle, and right point to the immunoreactive bands that correspond to 
fusion protein FP3 (38 kD), full-length epidermal desmoglein-1 (160 kD), 
and the product encoded by pSVL-DG1A (96 kD) , respectively. 
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was shown to react specifically with the FP3 desmoglein-1 fusion 
protein that was used as the immunogen (Fig 2, lift) and with 
full-length desmoglein-1 from a human epidermal extract (Fig 2, 
middle). A 96-kD polypeptide expressed by desmoglein-1-trans-
fected COS-1 cells was also specifically recognized by this anti-
desmoglein-1 antiserum by immunoblot (Fig 2, right). 
The COS-1 transfectants were then analyzed by indirect IF. In 
the initial analysis, the cells were labeled with rabbit antisera, 
R-FP1 (prepared against the extracellular domain of human des-
moglein-1) and R-FP4 (which recognizes the desmoglein-1 cyto-
plasmic domain). As predicted, R-FP1 antiserum reacted with both 
viable and membrane-permeabilized COS/desmoglein-1 transfec-
tants (Fig 3A,q. In contrast, R-FP4 did not react with viable 
COS/ desmoglein-1 transfectants but showed strong, specific reac-
tivity with COS/ desmoglein-1 transfectants after membrane per-
meabilization (Fig 3B,D). Neither R-FP1 nor R-FP4 antisera 
showed reactivity with viable or permeabilized COS-1 cells trans-
fected with the pSVL vector. Another rabbit antiserum, R-FP3, 
which binds to the desmoglein-1 ectodomain by immunoblot 
analysis but is negative by indirect IF analysis of human skin, also 
failed to react with viable desmoglein-1-transfected cells. These 
results indicate that in COS/ desmoglein-1 transfectants the trans-
gene product was expressed as a surface protein in the appropriate 
transmembrane orientation. 
PF Autoantibody Reactivity With rDsgl Ectodomain Is 
IgG4 Restricted Anti- desmoglein-1 reactivity exhibited by FS 
sera was analyzed further for IgG subclass restriction. COS/ 
desmoglein-1 transfectants and vector-transfected control cells 
were labeled with FS and control sera, and the bound autoantibod-
ies were visualized by indirect IF using monoclonal anti-human IgG 
subclass-specific secondary antibodies. The results of this analysis in 
the five FS sera that were tested demonstrated that reactivity with 
rDsg1 was largely accounted for by IgG4 autoantibodies (Fig 4). 
Low levels of IgG 1 and IgG2 reactivity also were detected in this 
assay. These patients' sera showed no reactivity with pSVL-
transfected COS-1 cells. 
Figure 3. rDsgl is expressed in the appropriate transmemb~an.e 
orientation. Desmoglein-l-transfected COS-l cells were labeled by mdl-
rect IF using rabbit antisera R-FPl (A,C) or R-FP4 (B,D). R-FPl, directed 
against the desmoglein-l ectodomain, showed strong reactivity with b~th 
nonpermeabilized (A) and permeabilized cells (C). R-FP4, prep~ed agamst 
a cytoplasmic segment of desmoglein-l , reacted with permeabilized ~:ms­
fectants (D) but showed only background labeling of nonpermeabilized 
cells (B). Bar, 60 j.Lm. 
FS-1 FS-2 
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Figure 4. FS reactivity to the rDsgl ectodomain is IgG4 restricted. 
COS/ desmoglein-l transfectants were labeled with FS sera (FS-l and 
FS-2), and immunoreactivity was visualized with human IgG subclass-
specific secondary antibodies. Reactivity of both of these FS sera with the 
transfectants was predominantly due to IgG4 autoantibodies. In addition, 
FS-l showed weak IgG2 reactivity and FS-2 showed weak IgG 1 reactivity 
with these cells. No IgG3 reactivity was found in the two FS sera shown. 
Bar, 60 j.Lm. 
The rDsgl Ectodomain Is Recognized by All PF and by a 
Subset ofPV Sera Viable COS/desmoglein-1 transfectants and 
control cells were assayed by indirect IF for reactivity with a panel 
of PF and control sera using an anti-human IgG4 secondary 
antibody. Representative results from this analysis are shown in Fig 
5, and the summary of all of the results is presented in Table I. All 
24 FS sera and five of seven nonendemic PF sera showed specific 
IgG4 reactivity with viable (nonpermeabilized) desmoglein-1-
transfected cells. The remaining two PF sera had previously been 
shown, by indirect IF analysis of normal human skin cryosections. 
to contain anti-epidermal autoantibodies that were exclusively of 
the IgG1 subclass. When tested with an anti-IgG1 secondary 
antibody, these two PF sera showed specific reactivity with viable 
desmoglein-1-transfected COS-1 cells. The bound human IgG4 (or 
IgG 1) typically displayed a punctate labeling pattern on the surface 
of the transfected cells (Fig 5). Of the 18 PV sera that were tested, 
10 showed specific reactivity with the COS/desmoglein-1 trans-
fectants. Control sera used in this analysis were obtained from 26 
unaffected individuals from the endemic areas of Brazil (14 of 
whom were relatives of FS patients) , 12 unaffected individuals from 
the United States, and 12 BP patients. None of these control sera 
reacted with the desmoglein-1 transfectants or with pSVL-trans-
fected COS cells. 
Immunoreactivity ofFS sera (FS-1 and FS-2) with COS/desmo-
glein-1 transfectants was almost completely abolished by pread-
sorption of the patient sera with a bovine epidermal envelope 
extract containing the previously characterized, 80-kD soluble 
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Figure 5. rDsgl is recognized by FS but not by 
control sera. COS-1 cells were transfected with 
either pSVL or with the desmoglein-1 (Dsg-1) 
expression construct. Patient serum FS-1 reacted 
with desmoglein-1-transfected cells but not with the 
control pSVL transfectants. Serum from an unaf-
fected relative of patient FS-1 (FS-1 REL) did not 
react with either the pSVL or the desmoglein-1 
transfectants. Right: COS/ desmoglein-1 transfec-
tants are not labeled with either normal human 
serum (top) or BP patient serum (bottom). Bar, 30 IJ-m. 
FS-1 
FS-1 
REL 
FS-reactive antigen [13-15]. Preadsorption of these sera with 
bovine serum albumin had no effect on their reactivity with 
COS/ desmoglein-1 transfectants. The results of this preadsorption 
analysis on serum FS-1 are shown in Fig 6. 
COS/desmoglein-1 transfectants were analyzed by indirect IF 
for reactivity with FS sera in the presence or absence of calcium. FS 
patient sera FS-1 and FS-2 showed strong reactivity with the 
transfected cells in the presence of calcium (Fig 7 , top), but showed 
little or no reactivity in the presence of the divalent cation chelator 
ethylenediaminetetraacetic acid (Fig 7 , bottom). These same two FS 
sera showed a similar calcium dependence in indirect IF staining of 
human skin cryosections (data not shown). 
DISCUSSION 
The aim of the present study was to develop a system for identifying 
and characterizing epitopes on desmoglein-1 that may be recog-
nized by pathogenic autoantibodies produced by PF patients. 
Several independent lines of evidence have previously indicated 
that conformational, rather than linear, epitopes may well be 
relevant in initiation of the disease process in these patients 
[13,14,21,22]. It has further been postulated that PF autoantibodies 
may manifest their pathogenic effects by binding to, and directly 
impairing the function of, a cell adhesion molecule (possibly 
desmoglein-1) [9,16,22]. Therefore, our approach in this study was 
to generate a recombinant form of desmoglein-1 using the COS-1 
expression system in an attempt to retain pathogenically relevant 
epitopes. 
Immunoblot analysis demonstrated that the COS/ desmoglein-1 
transfectants synthesized a polypeptide with an apparent molecular 
weight of 96 kD that was recognized by a well-characterized 
anti-desmoglein-1 antiserum. This observed molecular weight 
differs significantly from the predicted sizes of both the primary 
translation product of the pSVL-DG1A construct (71.7 kD) and the 
processed form of this recombinant protein (65.7 kD; based on the 
assumption that its amino terminus is proteolytically processed as in 
the epidermal form of desmoglein-1; see [17]). It is of interest to 
note that desmoglein-1 isolated from epidermis (predicted size 110 
kD) also runs aberrantly on a sodium dodecylsulfate gel (apparent 
molecular weight 160-165 kD), presumably because of post-
translational processing. The ratio of the predicted and experimen-
tally determined sizes of human epidermal desmoglein-1 (0.69) is 
nearly identical to that of the recombinant form (0.68). These 
observations suggest that the pSVL-DG1A product expressed in 
COS-1 cells may undergo post-translational processing similar to 
that of wild-type desmoglein-1. 
Our efforts to identify a specific antigen/antibody system(s) 
involved in initiating blister formation in PF have focused on 
autoantibody-reactive determinants located on the extracellular 
domain of native desmoglein-1-sites that are predicted to be 
accessible to components of the immune system before tissue 
damage. One method designed to characterize such antigen/ 
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antibody systems involves indirect IF analysis of PF patient and 
control sera with viable (nonpermeabilized) COS/ desmoglein-1 
transfectants. This method was validated with the use of well-
characterized rabbit anti- desmoglein-1 antibodies. A rabbit anti-
body (R-FP4) directed against a cytoplasmic segment of desmo-
glein-l labeled desmoglein-1-transfected cells, but only after the 
cells were permeabilized. In contrast, rabbit antiserum R-FP1, 
which recognizes an extracellular site on desmoglein-1 and which 
shows keratinocyte surface labeling in human skin cryosections, 
yielded an intense, punctate surface-labeling pattern on viable 
COS/desmoglein-1 transfectants. A rabbit antiserum that reacts 
with a denaturation-dependent site on the desmoglein-1 ectodo-
main failed to react with viable desmoglein-1-transfected cells. 
Thus, IF labeling of viable COS/desmoglein-l transfectants ap-
pears to be a useful tool for detecting and characterizing confor-
mational epitopes on the extracellular domain of desmoglein-1. 
Five FS sera were assayed for reactivity with viable COS/ 
desmoglein-1 transfectants using IgG subclass-specific secondary 
antibodies. In all five cases, the autoantibody response against the 
desmoglein-1 ectodomain was shown to be largely due to IgG4 
autoantibodies. Lower levels ofIgG1 and IgG2 reactivity also were 
detected in this assay system. The results of this IgG subclass 
analysis correlated very well with the subclass restriction detected 
in these same sera by the conventional indirect IF analysis on 
normal human skin cryosections (data not shown). These results 
suggest that autoantibody reactivity directed against the desmo-
glein-1 ectodomain accounts for the great majority of PF immuno-
reactivity detected by indirect IF analysis on human skin. 
We expanded this initial IgG subclass analysis by assaying a large 
Table I. PF and PV Sera Contain IgG4 Autoantibodies 
Directed Against the Desmoglein-l Ectodomain 
Serum Source 
FS patients 
PF patients 
PV patients 
FS relatives from 
endemic areas 
Normal controls living 
in endemic areas 
BP patients 
Normal controls living 
in the u.S. 
Number Tested 
24 
7 
18 
14 
12 
12 
12 
IgG4 Indirect 
IF Reactivity With 
Viable COS/Desmoglein-1 
Transfectants 
All 24 sera positive 
All 7 sera positive" 
10 of 18 sera positive 
All sera negative 
All sera negative 
All sera negative 
All sera negative 
a Two of the seven nonendemic PF sera contained anti-epidemlal autoantibodies 
that were exclusi ely of the IgG 1 subclass. These two sera exhibited IgG 1 reactivity 
with the COS/ desmoglein-l transfectants . 
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Figure 6. The bovine PF antigen (BOV. PF AG) blocks PF reactiv-
ity with rDsgl. Desmoglein-1 transfectants showed strong reactivity with 
the FS-1 patient serum preadsorbed with bovine serum albumin (BSA) (top). 
However, pre adsorption of the same FS serum with a bovine epidermal 
preparation containing the 80-kD fragment of desmoglein-1 (see [14,15]) 
abolished reactivity with desmoglein-1-transfected cells (bottom). Bar, 30 
JJ.-m. 
panel of pemphigus and control sera for reactivity with viable 
desmoglein-1-transfected cells using an anti-IgG4 subclass-specific 
secondary antibody. All 24 FS sera and five of seven PF sera were 
shown to contain IgG4 autoantibodies that recognized these cells. 
The remaining two PF sera exhibited IgG1 reactivity in this assay 
system. These data represent the first direct demonstration that an 
autoimmune response (predominantly IgG4) specifically directed 
against the extracellular domain of desmoglein-1 is a characteristic 
of PF. These findings are highly significant in light of previous 
findings that the IgG4 fraction of PF patients' sera contains the 
majority of the pathogenic activity, as determined by the neonatal 
mouse passive transfer model [7]. Also relevant is the reported 
correlation between the indirect IF titers of PF sera and levels of 
disease activity [29]. Taken together, these findings suggest that the 
immunoreactivity detected in the COS/ desmoglein-1 IF assay 
system may be relevant to pathogenesis. 
Observations presented here and reported previously suggest that 
conformational epitopes are important in PF. All PF sera typically 
label the surface of human epidermal keratinocytes by indirect 
IF [2,3] and react with desmoglein-1 by immunoprecipitation 
[10,11,13-15]. In contrast, by immunoblot analysis only about half 
ofPF sera show reactivity with either full-length human epidermal 
desmoglein-1 [11] or bacterial fusion proteins containing segments 
of the desmoglein-1 ectodomain [21]. The fact that the desmo-
glein-1-transfected COS cells were labeled by all PF sera is a strong 
indication that conformational desmoglein-1 epitopes that may be 
relevant in the disease process are retained in this expression 
system. 
Antibody reactivity to rDsg1 expressed on COS cells was shown 
to be disease-specific for the pemphigus group. Whereas all PF and 
FS sera were positive in this assay, none of the control sera (BP and 
normal) showed any reactivity with the desmoglein-1-transfected 
cells. It is interesting that 10 of 18 PV sera also exhibited IgG4 
reactivity with viable COS/desmoglein-1 transfectants. This result 
is consistent with previous reports that a subset of PV sera reacts 
FS-1 FS-2 
Ca++ 
EDTA 
Figure 7. Reactivity ofPF autoantibodies with COS/desmoglein-l 
transfectants is Ca + + dependent. Desmoglein-1-transfected COS-1 
cells were labeled with sera FS-1 and FS-2 in the presence of either 1 mM 
calcium or 5 mM ethylenediamine tetraacetic acid (EDT A). Both FS sera 
reacted strongly with the transfectants in the presence of calcium (top); 
however, this reactivity was abolished by addition of ethylenediamine 
tetraacetic acid to the reaction mixture (bottom). Bar, 30 JJ.-m. 
with desmoglein-1 [10,13,14]. However, the information pre-
sented here represents the first direct demonstration that PV 
autoantibodies react with the extracellular domain of desmo-
glein-1. The pathogenic relevance of the anti- desmoglein-1 auto-
immune response exhibited by PV patients remains unclear. 
Previous reports have demonstrated that calcium is essential for 
reactivity ofPF autoantibodies with human keratinocytes, as deter-
mined by indirect IF [30]. Calcium was also shown previously to be 
important in the reactivity of FS autoantibodies with solubilized 
desmoglein-1 [31] and with the 80-kD desmoglein-1 peptide 
[13,14,32]. In this investigation, we have shown that reactivity of 
FS IgG4 autoantibodies with rDsg1 expressed by COS-1 cells is also 
a calcium-dependent interaction. The calcium-dependent immuno-
reactive site of desmoglein-1 was shown to be accessible to 
antibodies in the absence of any protein-denaturing agents and was 
mapped to the extracellular domain of desmoglein-1 based on the 
fact that the antibody-binding assay was performed on viable 
COS-l transfectants. It is noteworthy that the extracellular domain 
of desmoglein-1 contains six putative calcium-binding sites [16-
19], one or more of which are likely to playa critical role in protein 
conformation and function. Binding of calcium to one or more of 
these sites also may be essential for PF autoantibody reactivity. 
The findings reported in this paper provide additional support for 
the hypothesis that the desmoglein-1 antigen/antibody system 
associated with PF and FS is directly involved in the disease process. 
Further, it appears likely that the ectodomain of desmoglein-l 
harbors pathogenically relevant epitope(s). Direct proof of this will 
require the use of neonatal mouse passive transfer studies to 
demonstrate the pathogenicity of a well-defined population of 
patient autoantibodies, e.g., autoantibodies affinity purified against 
a segment of the human desmoglein-l ectodomain. The develop-
ment of a mammalian expression system, such as the COS/ 
desmoglein-1 transfectants described in this study, should greatly 
facilitate these future studies. 
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